Objectives: Several animal disease models have been used to understand the mechanisms of systemic lupus erythematosus (SLE); however, the translation of findings from animals to humans has not been sufficiently examined in drug development. To confirm the validity of New Zealand black x New Zealand white (NZB/W) F1 mice as an SLE model, we extensively characterized SLE patients and NZB/W F1 mice by omics analysis.

Methods: Peripheral blood from patients and mice and spleen and lymph node tissue from mice were analysed using cell subset analysis, cytokine panel assays, and transcriptome analysis.

Results: CD4+ effector memory T cells, plasmablasts, and plasma cells were increased in both SLE patients and NZB/W F1 mice. Levels of tumor necrosis factor-α, interferon gamma induced protein-10, and B cell activating factor in plasma were significantly higher in SLE patients and NZB/W F1 mice than in their corresponding controls. Transcriptome analysis revealed an upregulation of genes involved in the interferon signalling pathway and T-cell exhaustion signalling pathway in both SLE patients and the mouse model. In contrast, death receptor signalling genes showed changes in the opposite direction between patients and mice.

Conclusion: NZB/W F1 mice are a generally suitable model of SLE for analysing the pathophysiology and treatment response of T/B cells and monocytes/macrophages and their secreted cytokines.

Download full-text PDF

Source
http://dx.doi.org/10.1093/mr/road024DOI Listing

Publication Analysis

Top Keywords

nzb/w mice
24
sle patients
16
patients nzb/w
12
systemic lupus
8
lupus erythematosus
8
mice
8
signalling pathway
8
sle
7
nzb/w
6
patients
6

Similar Publications

Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus.

Arthritis Res Ther

November 2024

GenNBio Inc, 80, Deurimsandan 2-ro, Cheongbuk-eup, Pyeongtaek-si, Gyeonggi-do, 17796, Republic of Korea.

Article Synopsis
  • Systemic lupus erythematosus (SLE) is a chronic, incurable autoimmune disease, prompting the need for effective treatments, such as using extracellular vesicles (EV) from mesenchymal stem cells (iMSCs) primed with immune cell media.
  • In the study, female NZB/W F1 mice were divided into three groups to assess the effects of CM-EV and ASC-EV treatments compared to a control group, with assessment done over 36 weeks.
  • Results showed that CM-EV treatment enhanced survival rates, reduced harmful antibodies, and improved kidney health, while both EV types decreased pro-inflammatory macrophages, indicating their potential in modulating SLE’s immune response.
View Article and Find Full Text PDF

Neuropilin-1 as a Key Molecule for Renal Recovery in Lupus Nephritis: Insights from an NZB/W F1 Mouse Model.

Int J Mol Sci

October 2024

Rheumatology Research Group-Lupus Unit, Vall d'Hebrón University Hospital, Vall d'Hebrón Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.

Article Synopsis
  • - Systemic lupus erythematosus (SLE) is an autoimmune disease affecting many organs, with lupus nephritis (LN) impacting 40-50% of patients and potentially leading to serious kidney complications like end-stage renal disease (ESRD).
  • - This study investigates the role of neuropilin-1 (NRP-1), a receptor in kidney tissue, as a biomarker for kidney recovery in LN using a mouse model, demonstrating a significant increase in NRP-1 levels over time.
  • - High urinary NRP-1 levels (above 34.40 ng/mL) were strongly associated with positive renal outcomes, highlighting NRP-1's potential as a reliable biomarker for kidney recovery in
View Article and Find Full Text PDF
Article Synopsis
  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs, with kidney issues (lupus nephritis) being a serious complication and a leading cause of death in affected patients.
  • Current mouse models used to study SLE/LN show diverse immune responses that may not fully reflect human disease, highlighting the need for better models that parallel human pathways for developing new treatments.
  • The research compared the immune responses of five different mouse models of SLE/LN to human data, finding differences in cell types and responses, which could help in understanding the disease and improving therapy translation for patients.
View Article and Find Full Text PDF
Article Synopsis
  • CD44 is a glycoprotein linked to kidney inflammation and fibrosis, specifically studied in a mouse model for lupus nephritis (LN) and in human patients with active LN.
  • The research showed that CD44 was absent in healthy kidneys but expressed in kidney cells of LN patients, and treatment with anti-CD44 antibodies improved kidney health in mice by reducing immune cell infiltration and fibrosis markers.
  • Serum CD44 levels increased before clinical symptoms of renal flare in patients, effectively distinguishing those with active LN from healthy individuals and other kidney-related conditions.
View Article and Find Full Text PDF
Article Synopsis
  • Lanthionine synthetase C-like 2 (LANCL2) is identified as a key immunoregulatory target in treating autoimmune diseases like systemic lupus erythematosus (SLE), with the investigational drug NIM-1324 aimed at improving patient outcomes.
  • In laboratory models, mice lacking LANCL2 exhibited severe symptoms of inflammation, while treatment with NIM-1324 enhanced regulatory T cell populations and reduced harmful inflammatory T cells, leading to overall better health markers.
  • NIM-1324 also showed efficacy in human immune cells from SLE patients, lowering pro-inflammatory cytokines and supporting a more balanced immune response, indicating its potential as a therapeutic option.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!